Drug Trial Radar · NCT06081621
A Clinical Study to Evaluate the Efficacy and Safety of REGEND001 Cell Therapy on Idiopathic Pulmonary Fibrosis (IPF)
Last checked: Nov 19, 2026Latest source record: Mar 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
23
Actual
Start
Dec 11, 2023
Primary completion
Mar 14, 2025
Study completion Mar 14, 2025
Sponsor
- Lead sponsor
- Regend TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- Peking Union Medical College Hospital; RenJi Hospital; Ruijin Hospital; Second Affiliated Hospital of Xiamen Medical College
- First posted
- Oct 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Idiopathic pulmonary fibrosis (IPF) is a serious chronic (long term) disease with injury of lung tissues. REGEND001 is a cell therapy product, made from bronchial basal cells with ability to regenerate lung tissue, is promising to IPF treatment. This is a multi-center, randomized, double-blinded, parallel and placebo-controlled phase II clinical study to evaluate the efficacy and safety of REGEND001 in IPF patients.
Conditions
- Idiopathic Pulmonary Fibrosis
Interventions
REGEND001Biological
REGEND001: 1-1.5×10\^6 bronchial basal cells/kg administrated by bronchoscopy.
PlaceboBiological
Placebo: Sodium chloride injection administrated by bronchoscopy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Comparison of the area under the curve (AUC) of DLCO measured values at each visit from baseline to week 24 between the REGEND001 group and the placebo group.Time frame: 12 and 24 weeks after treatment
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
The Second Affiliated Hospital of Xiamen Medical College
Xiamen, Fujian, China
Ruijin Hospital, Shanghai Jiaotong University School Of Medicine
Shanghai, Shanghai Municipality, China
Renji Hospital, Shanghai Jiaotong University School Of Medicine
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.